Open AccessImportance of using a pharmacogenetic approach to predict individual pharmacokinetics and safety profile of apixaban
Author(s) -
Л. В. Федина,
И. Н. Сычев,
D. А. Sychev
Publication year - 2022
Publication title -
farmakogenetika i farmakogenomika
Language(s) - English
Resource type - Journals
eISSN - 2686-8849
pISSN - 2588-0527
DOI - 10.37489/2588-0527-2021-1-4-8
Subject(s) - apixaban , pharmacogenetics , pharmacokinetics , medicine , pharmacodynamics , pharmacology , warfarin , rivaroxaban , genotype , biology , genetics , atrial fibrillation , gene
In recent years, there has been a trend towards increased prescribing of direct-acting oral anticoagulants (DOACs) due to favourable pharmacokinetics and pharmacodynamics without the need for regular coagulation monitoring. However, recent studies have documented individual variability in plasma DOAC levels. DOAC pharmacogenetics is a relatively new area of research. There is a need to understand the role of pharmacogenetics in the adaptation of anticoagulant therapy according to a patient’s genetic characteristics. This scientific review of current data on the impact of different gene polymorphisms on apixaban pharmacokinetics broadens the understanding of the clinical relevance of genotyping for treatment efficacy and safety.